Consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Net revenues	$ 655,353	$ 605,220	$ 509,338
Cost of revenues	166,879	137,181	128,280
Gross profit	488,474	468,039	381,058
Operating costs and expenses:
Research, development and clinical studies	224,544	209,645	223,062
Sales and marketing	240,064	239,063	226,809
General and administrative	177,666	189,827	164,057
Total operating costs and expenses	642,274	638,535	613,928
Operating income (loss)	(153,800)	(170,496)	(232,870)
Financial (expenses) income, net	17,550	39,334	41,130
Total income (loss) before income taxes	(136,250)	(131,162)	(191,740)
Income tax	(23)	37,465	15,303
Net income (loss)	$ (136,227)	$ (168,627)	$ (207,043)
Basic net income (loss) per ordinary share (in usd per share)	$ (1.22)	$ (1.56)	$ (1.95)
Diluted net income (loss) per ordinary share (in usd per share)	$ (1.22)	$ (1.56)	$ (1.95)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	111,471,991	107,834,368	106,391,178
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	111,471,991	107,834,368	106,391,178